Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDT with Porfimer Sodium for Unresectable Advanced Perihilar Cholangiocarcinoma
NCT02082522Phase 3Terminated
- Sponsor
- Concordia Laboratories
- Start
- Nov 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of porfimer sodium in perihilar cholangiocarcinoma (PHC) (2 arms), sponsored by Concordia Laboratories. Primary endpoint: Overall Survival Time at 26 months. Started Nov 2014; status: terminated.
02
Drugs
porfimer sodium
03
Conditions
perihilar cholangiocarcinoma (PHC)
Beyond the preview
Go deeper on NCT02082522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02082522.